FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Jad Othman(King's College London), Richard Dillon(King's College London), James Aries(Queen Mary University of London), Pramila Krishnamurthy(King's College London), Paraskevi Gkreka(Princess Royal University Hospital), Caroline Furness(Royal Marsden NHS Foundation Trust), Panagiotis Kottaridis(University College Hospital), Dominic Culligan(Aberdeen Royal Infirmary), Jenny O’Nions(University College London Hospitals NHS Foundation Trust), Amanda Gilkes(Cardiff University), Katya Mokretar, Sylvie Freeman(University of Birmingham), Manish Jain(University of Iowa), Edward Belsham(Portsmouth Hospitals NHS Trust), Nigel H. Russell(Nottingham University Hospitals NHS Trust), Tom Rider(Thomas Jefferson University), David Taussig(Institute of Cancer Research), Marianne Tang Severinsen(Aalborg University Hospital), Unmesh Mohite(Singleton Hospital), Eibhlin Conneally(St. James's Hospital), Mike Dennis(The Christie NHS Foundation Trust), Anjum Khan(Leeds Teaching Hospitals NHS Trust), Wing Roberts(Great North Children's Hospital), Mariam Amer(University Hospital Southampton NHS Foundation Trust), Caroline Duncan(Raigmore Hospital), Paul Cahalin(Blackpool Teaching Hospitals NHS Foundation Trust), Neill Storrar(NHS Lothian), Mary Frances McMullin(Queen's University Belfast), Charles Craddock(Queen Elizabeth Hospital Birmingham), Nicola Potter(European Bioinformatics Institute), Andrew King(Addenbrooke's Hospital), Anne‐Louise Latif(Queen Elizabeth University Hospital), Katharine Patrick(Sheffield Children's NHS Foundation Trust), Wendy Ingram(University Hospital of Wales), Katherine Hodgson(University of Leicester), Loretta Ngu(Royal Devon & Exeter NHS Foundation Trust), Steven Knapper(Cardiff University)
Cited by 48
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k